Moderna also released the data of eight participants that showed the presence of neutralizing antibodies that either reached or exceeded the amount found in people who have naturally recovered from COVID-19.
Scientists at Moderna found that all participants managed to develop antibodies against SARS-CoV-2, the virus that causes COVID-19.
In partnership with the U.S. National Institutes of Health (NIH), Moderna just completed early human trials of its mRNA 1273 COVID-19 vaccine candidate and the results are extremely promising.
Now it's being repurposed to treat COVID-19 as part of the World Health Organization's (WHO) Solidarity Trial, a global effort to find a vaccine for the COVID-19.
Even before all the clinical trials are completed, Moderna wants to begin production of its eventual vaccine in order to buffer the high global demand.